Please wait while the formulary information is being retrieved.
ONUREG (azacitidine)
- Acute myeloid leukemia
200 mg tablet
- 1 tablet (200 mg) by oral route once daily on days 1 through 14 of a 28-day cycle
300 mg tablet
- 1 tablet (300 mg) by oral route once daily on days 1 through 14 of a 28-day cycle
Default screening record
- 1 tablet (200 mg) by oral route once daily on days 1 through 14 of a 28-day cycle
- 1 tablet (200 mg) by oral route once daily on days 1 through 7 of a 28-day cycle
- 1 tablet (300 mg) by oral route once daily on days 1 through 14 of a 28-day cycle
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- None
ONUREG (azacitidine)
- Acute myeloid leukemia
- None
- None
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Azacitidine
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
Azacitidine
Renal-Monitor renal function in elderly since they have a higher incidence of drug induced renal dysfunction.
Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
Increased Risk / Adverse Effects | Y | Y | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
Acute myeloid leukemia | |
C92.0 | Acute myeloblastic leukemia |
C92.00 | Acute myeloblastic leukemia, not having achieved remission |
C92.02 | Acute myeloblastic leukemia, in relapse |
C92.4 | Acute promyelocytic leukemia |
C92.40 | Acute promyelocytic leukemia, not having achieved remission |
C92.42 | Acute promyelocytic leukemia, in relapse |
C92.5 | Acute myelomonocytic leukemia |
C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
C92.52 | Acute myelomonocytic leukemia, in relapse |
C92.6 | Acute myeloid leukemia with 11q23-abnormality |
C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
C93.0 | Acute monoblastic/monocytic leukemia |
C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
C94.4 | Acute panmyelosis with myelofibrosis |
C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
0-9 | A-Z |
---|---|
C92.0 | Acute myeloblastic leukemia |
C92.00 | Acute myeloblastic leukemia, not having achieved remission |
C92.02 | Acute myeloblastic leukemia, in relapse |
C92.4 | Acute promyelocytic leukemia |
C92.40 | Acute promyelocytic leukemia, not having achieved remission |
C92.42 | Acute promyelocytic leukemia, in relapse |
C92.5 | Acute myelomonocytic leukemia |
C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
C92.52 | Acute myelomonocytic leukemia, in relapse |
C92.6 | Acute myeloid leukemia with 11q23-abnormality |
C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
C93.0 | Acute monoblastic/monocytic leukemia |
C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
C94.4 | Acute panmyelosis with myelofibrosis |
C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
Formulary Reference Tool